Researchers at UT Southwestern Medical Center and in Australia have shown that a drug currently in testing shows potential to cure malaria in a single dose and offers promise as a preventive treatment as well.
The new drug – DSM265 kills drug-resistant malaria parasites in the blood and liver by targeting their ability to replicate. Malaria is a highly infectious, mosquito-transmitted disease that kills nearly 600,000 people worldwide each year, mostly children under 5 years old living in sub-Saharan Africa. Nearly 200 million cases of malaria are reported annually, and about 3 billion people are at risk of malaria in 97 countries.
“DSM265 could be among the first single-dose cures for malaria, and would be used in partnership with another drug,” said lead author Dr. Margaret Phillips, Professor of Pharmacology at UT Southwestern. “The drug also could potentially be developed as a once-weekly preventive.”
The research team included UT Southwestern, the Monash Institute of Pharmaceutical Sciences in Australia, the University of Washington, and the not-for-profit Medicines for Malaria Venture (MMV). The study was published inScience Translational Medicine.
Researchers determined that the compound DSM265 kills the malaria parasite Plasmodium in both liver and blood stages of infection. Further, the compound was shown to be well tolerated and effective in preclinical models.
Currently, the frontline anti-malarial treatments are artemisinin-based combination therapies, or ACTs, which are credited with helping to reduce the malaria burden. However, malaria strains resistant to ACTs have recently been reported in Thailand, Cambodia, Vietnam, Myanmar, and Laos.
“The problem is we’re starting to see more drug resistance, and this is what’s taken out every anti-malarial drug we’ve had,” said Dr. Phillips, who holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science, and the Carolyn R. Bacon Professorship in Medical Science and Education. “The parasite is very good at adapting and becoming resistant to drugs ? this is inevitable. What we can do is deliver new medicines with new modes of action and safeguard the longevity of the anti-malarial through use in combination as long as possible.”
In order to combat drug resistance, DSM265 likely would be partnered with another new drug and used as a one-dose combination therapy. Another option is to develop DSM265 as a once-weekly preventive for individuals traveling to malaria-endemic regions or for people living in areas where malaria infections are primarily seasonal and human immunity is low. Either scenario is still several years away, pending the outcome of current and future trials, said Dr. Phillips.
DSM265 targets the ability of the parasite to synthesize the nucleotide precursors required for synthesis of DNA and RNA, said Dr. Phillips.
The study concluded that DSM265 appeared to be safely tolerated in non-human tests and established optimal dosing levels and length of drug effectiveness in preclinical models to estimate dosing for humans, paving the way for clinical trials. The first clinical trial was a safety study in Australia, followed by an ongoing efficacy study in Peru to evaluate the ability to treat patients with malaria. Additional human studies are planned, including one to test the drug as a preventive medicine. UT Southwestern is assisting in an advisory capacity in these studies and is providing support with biomarker assays.
The Latest on: Malaria
via Google News
The Latest on: Malaria
- Study Connects Climate Hazards to 58% of Infectious Diseases Like Cholera and Malariaon August 8, 2022 at 8:17 pm
Climate hazards such as flooding, heat waves and drought have worsened more than half of the hundreds of known infectious diseases in people, including malaria, hantavirus, cholera and anthrax, a ...
- Drugs for Malaria Market In-Depth Analysis of Industry Share, Size, Growth Outlook up to 2028 with Top Countries Dataon August 8, 2022 at 5:51 pm
Aug 08, 2022 (The Expresswire) -- "Drugs for Malaria Market" Insights 2022 By Types, Applications, Regions and Forecast to 2028. The global Drugs for ...
- Hong Kong logs 77 imported malaria infections, 2 people in serious conditionon August 8, 2022 at 4:20 am
Hong Kong has reported 77 imported malaria cases, health authorities have said. Forty-seven people are being treated at public hospitals, two of whom are in a serious condition. The city has recorded ...
- Monoclonal Antibody Treatment Shows Promise in Preventing Malariaon August 7, 2022 at 7:30 am
A singular injection of a monoclonal antibody treatment candidate has been shown as safe and highly protective in US adults exposed to malaria. The corresp | Drug Discovery And Development ...
- In the 1880s, D.C.’s doctors argued about malaria and its causeon August 6, 2022 at 9:00 am
Malaria — literally, if not scientifically, "bad air" — once claimed Washingtonians by the score. So why did some doctors believe it wasn't real?
- Monoclonal Antibody Prevents Malaria in Clinical Trialon August 5, 2022 at 5:00 am
Results from a Phase I clinical trial have shown that a monoclonal antibody known as L9LS is safe and highly protective in U.S. adults exposed to the malaria parasite. The use of this antibody could ...
- Lab-engineered antibody appears to protect from malaria, study showson August 4, 2022 at 11:41 am
U.S. government researchers found that a lab-engineered antibody protected most participants from infection with the malaria parasite -- including all of those who received a higher dose of the ...
- Monoclonal Antibody Might Help Prevent Malariaon August 4, 2022 at 4:38 am
Researchers are reporting early but encouraging findings on a potential new way to prevent malaria — an old foe that still ranks as ...
- Monoclonal antibody prevents malaria in US adults, NIH trial showson August 3, 2022 at 5:00 pm
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National ...
- WHO moves to roll out first malaria vaccine in Africaon July 21, 2022 at 4:00 am
BLANTYRE, Malawi — As the World Health Organization announces the next step in its rollout of the world’s first authorized malaria vaccine in three African countries, concerns about its value ...
via Bing News